(Q414463)

Tapentadol (English)

3 October 2016

C₁₄H₂₃NO

1 reference

Tapentadol (English)

19 November 2016

CCC(C1=CC(=CC=C1)O)C(C)CN(C)C

1 reference

Tapentadol (English)

19 November 2016

CC[C@@H](C1=CC(=CC=C1)O)[C@@H](C)CN(C)C

1 reference

https://www.whocc.no/atc_ddd_index/?code=N02AX06

Tapentadol (English)

19 November 2016

0.4 gram

route of administration

oral administration

1 reference

reference URL

1 reference

14 February 2018

medical condition treated

fibromyalgia

1 reference

Drug Indications Extracted from FAERS

significant drug interaction

2 October 2018

isocarboxazid

1 reference

High-priority drug–drug interactions for use in electronic health records

phenelzine

1 reference

High-priority drug–drug interactions for use in electronic health records

procarbazine

1 reference

High-priority drug–drug interactions for use in electronic health records

(±)-deprenyl

1 reference

High-priority drug–drug interactions for use in electronic health records

tranylcypromine

1 reference

High-priority drug–drug interactions for use in electronic health records

pethidine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

pethidine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

tramadol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

tramadol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

morphine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

morphine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

oxycodone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

oxycodone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

hydromorphone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

hydromorphone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

dihydrocodeine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

dihydrocodeine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

codeine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

codeine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

remifentanil

1 reference

A reference set of clinically relevant adverse drug-drug interactions

remifentanil

1 reference

A reference set of clinically relevant adverse drug-drug interactions

alfentanil

1 reference

A reference set of clinically relevant adverse drug-drug interactions

alfentanil

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sufentanil

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sufentanil

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-methadone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-methadone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

fentanyl

1 reference

A reference set of clinically relevant adverse drug-drug interactions

fentanyl

1 reference

A reference set of clinically relevant adverse drug-drug interactions

chlorpheniramine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

paroxetine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

imipramine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

clomipramine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

levomepromazine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

levomepromazine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

trimeprazine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

trimeprazine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

nitrazepam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

nitrazepam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

zopiclone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

zopiclone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

clobazam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

clobazam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

periciazine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

periciazine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

dexmedetomidine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

dexmedetomidine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-sulpiride

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-sulpiride

1 reference

A reference set of clinically relevant adverse drug-drug interactions

perampanel

1 reference

A reference set of clinically relevant adverse drug-drug interactions

perampanel

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(±)-thiopental

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(±)-thiopental

1 reference

A reference set of clinically relevant adverse drug-drug interactions

midazolam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

midazolam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-baclofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-baclofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

diazepam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

diazepam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

oxazepam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

oxazepam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

phenobarbital

1 reference

A reference set of clinically relevant adverse drug-drug interactions

phenobarbital

1 reference

A reference set of clinically relevant adverse drug-drug interactions

droperidol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

droperidol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

zolpidem

1 reference

A reference set of clinically relevant adverse drug-drug interactions

zolpidem

1 reference

A reference set of clinically relevant adverse drug-drug interactions

primidone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

primidone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

flurazepam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

flurazepam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

aripiprazole

1 reference

A reference set of clinically relevant adverse drug-drug interactions

aripiprazole

1 reference

A reference set of clinically relevant adverse drug-drug interactions

haloperidol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

haloperidol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

quetiapine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

quetiapine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sodium oxybate

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sodium oxybate

1 reference

A reference set of clinically relevant adverse drug-drug interactions

alprazolam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

alprazolam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

lorazepam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

lorazepam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

clonazepam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

clonazepam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

chlordiazepoxide

1 reference

A reference set of clinically relevant adverse drug-drug interactions

chlordiazepoxide

1 reference

A reference set of clinically relevant adverse drug-drug interactions

geniospasm

1 reference

A reference set of clinically relevant adverse drug-drug interactions

mental status change

1 reference

A reference set of clinically relevant adverse drug-drug interactions

hyperthermia

1 reference

A reference set of clinically relevant adverse drug-drug interactions

hypertension

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(±)-promethazine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(±)-promethazine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(±)-promethazine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

pimozide

1 reference

A reference set of clinically relevant adverse drug-drug interactions

pimozide

1 reference

A reference set of clinically relevant adverse drug-drug interactions

pimozide

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-hydroxyzine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-hydroxyzine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-hydroxyzine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

olanzapine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

olanzapine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

olanzapine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

loxapine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

loxapine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

loxapine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

chlorpromazine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

chlorpromazine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

chlorpromazine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

clozapine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

clozapine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

clozapine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

physically interacts with

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Solute carrier family 6 member 2

17 August 2016

subject has role

agonist

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Australian pregnancy category C

17 August 2016

pregnancy category

1 reference

imported from Wikimedia project

English Wikipedia

US pregnancy category C

1 reference

imported from Wikimedia project

0 references

Tapentadol

0 references

Identifiers

InChI

InChI=1S/C14H23NO/c1-5-14(11(2)10-15(3)4)12-7-6-8-13(16)9-12/h6-9,11,14,16H,5,10H2,1-4H3/t11-,14+/m0/s1

1 reference

Tapentadol (English)

19 November 2016

2 references

Tapentadol (English)

19 November 2016

ChEBI release 2020-09-01

CAS Registry Number

175591-23-8

2 references

tapentadol (English)

19 November 2016

https://commonchemistry.cas.org/detail?cas_rn=175591-23-8

9 April 2021

1 reference

Tapentadol (English)

19 November 2016

2 references

Tapentadol (English)

19 November 2016

ChEBI ID

135935

mapping relation type

exact match

2 references

ChEBI release 2019-10-02

International Chemical Identifier

InChI

InChI=1S/C14H23NO/c1-5-14(11(2)10-15(3)4)12-7-6-8-13(16)9-12/h6-9,11,14,16H,5,10H2,1-4H3/t11-,14+/m0/s1

1 reference

TAPENTADOL (English)

19 November 2016

2 references

inferred from InChIKey

Hazardous Substances Data Bank

1 reference

1 reference

28 October 2019

Tapentadol (English)

10 May 2021

2 references

Mapping file of InChIStrings, InChIKeys and DTXSIDs for the EPA CompTox Dashboard

DSSTOX compound identifier

0 references

0 references

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

100.131.247

27 December 2018

ECHA Substance Infocard ID

Phenol, 3-[(1R,2R)-3-(dimethylamino)-1-ethyl-2-methylpropyl]- (English)

quotation

CAS no.: 175591-23-8 (English)

100.131.247

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

100.131.247

27 December 2018

Phenol, 3-[(1R,2R)-3-(dimethylamino)-1-ethyl-2-methylpropyl]- (English)

quotation

CAS no.: 175591-23-8 (English)

1 reference

Tapentadol (English)

publication date

17 November 2015

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

D02.455.426.559.389.657.926

tapentadol (English)

19 November 2016

Tapentadol

0 references

MeSH concept ID

M0515162

0 references

MeSH tree code

0 references

RxNorm ID

787390

1 reference

tapentadol (English)

19 November 2016

1 reference

2 references

tapentadol (English)

19 November 2016

MedlinePlus drug identifier

a610006

0 references

PatientsLikeMe treatment ID

0 references

1 reference

tapentadol (English)

19 November 2016

0 references

1 reference

1 reference

https://docs.openalex.org/download-snapshot/snapshot-data-format

Tapentadol (English)

19 January 2016

0 references

1 reference

28 October 2013

Microsoft Academic ID

0 references

1 reference

26 January 2022

UMLS CUI

C2001271

1 reference